UPDATE: Piper Sandler Starts Marker Therapeutics (MRKR) at Overweight, $6 PT

March 25, 2021 4:53 AM EDT
Get Alerts MRKR Hot Sheet
Price: $2.13 -2.74%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 42
Trade Now! 
Join SI Premium – FREE
(Updated - March 25, 2021 8:30 AM EDT)

Piper Sandler analyst Joseph Catanzaro initiates coverage on Marker Therapeutics (NASDAQ: MRKR) with an Overweight rating and a price target of $6.00.

The analyst commented, "We are initiating coverage of Marker Therapeutics with an Overweight rating and a $6 PT. We view the MultiTAA platform as a highly differentiated T-cell therapy that offers multiple potential distinct advantages at both clinical efficacy and safety, as well as manufacturability. Baylor has generated a robust data set illustrating its remarkable safety profile and proof of concept clinical efficacy across multiple indications. With a potentially registrational Phase II AML trial now enrolling, we see significant opportunity for MRKR shares to appreciate as the MultiTAA platform is advanced through the clinic and generates additional validating data in support of its clinical utility."

For an analyst ratings summary and ratings history on Marker Therapeutics click here. For more ratings news on Marker Therapeutics click here.

Shares of Marker Therapeutics closed at $2.33 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage